Endocrinopathies with Use of Cancer Immunotherapies

ConclusionsOver 12% of patients receiving ipilimumab, nivolumab, and/or pembrolizumab in our study sample developed an endocrine IRAE. Patients who undergo treatment with immunomodulatory therapies should be monitored for the development of endocrine IRAEs.This article is protected by copyright. All rights reserved.

Source: Clinical Endocrinology - September 23, 2017 Category: Endocrinology Authors: Natalie M. Villa, Abtin Farahmand, Lin Du, Michael W. Yeh, Stephanie Smooke ‐Praw, Antoni Ribas, Bartosz Chmielowski, Grace Cherry, Angela M. Leung Tags: Original Article Source Type: research